Why the study?
Do CYP2C19 and CES1 gene variants affect clopidogrel metabolism in a South Asian population from Sri Lanka?
Do CYP2C19 and CES1 gene variants affect clopidogrel metabolism in a South Asian population from Sri Lanka?
CYP2C19 and CES1 gene variants significantly affect clopidogrel metabolism in Sri Lankans, suggesting a high prevalence of poor responders in South Asia and highlighting the potential need for genotype-guided antiplatelet therapy.
Hypothesis-generating for genotype-guided therapy in South Asians; prospective outcome trials needed before practice change.
AIMS: gene variants on clopidogrel metabolism in Sri Lankans, revealing significant pharmacogenomic insights with broader implications for South Asians. MATERIALS & METHODS: gene were studied. RESULTS: < 0.05). CONCLUSION: Given that South Asians share genetic similarities, these findings suggest that a substantial proportion of the region's population may also be poor responders to clopidogrel, increasing the risk of adverse outcomes. This highlights the importance of genotype-guided antiplatelet therapy, which could improve clinical outcomes across South Asia amidst rising cardiovascular disease rates.
No takes yet. Share an insight, caveat, or question.
Ranasinghe et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: